Taken together, the evidence presented here are encouraging towards the desired pharmacokinetic profile for V56B2 as a single product that will deliver saturating, therapeutic concentrations of both V565 and V900 to the inflamed mucosa in IBD patients, for neutralisation of TNFα and IL-23, but without systemic immunosuppression. This evidence concerns the gene IL23A and inflammatory bowel disease.